GNLX

#3925
Genelux Corporation Common Stock
2.64 USD
+4.35%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.64
2.64
Intervallo Annuale
2.25
8.54
Variazione giornaliera
+4.35%
Variazione Mensile
0.00%
Variazione di 6 mesi
-50.00%
Variazione Annuale
+5.18%
Chiusura Precedente
2.53
Apertura
2.64
Bid
Ask
Minimo
2.64
High
2.64
Volume
9
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 118.29 M
  • Employee 26
  • Founded 2001
  • CEO N/A
  • Website www.genelux.com
  • Headquarter Delaware, United States
  • FIGI BBG0044BNBX6
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-5.07
Rapporto prezzo/fatturato
20.26 K

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

Notizie